Advertisement
ResearchIn-Press PreviewGastroenterologyInfectious disease
Open Access | 10.1172/JCI170859
1Pathology & Immunology, Baylor College of Medicine, Houston, United States of America
2Rice University, Houston, United States of America
Find articles by Wu, Q. in: JCI | PubMed | Google Scholar
1Pathology & Immunology, Baylor College of Medicine, Houston, United States of America
2Rice University, Houston, United States of America
Find articles by Badu, S. in: JCI | PubMed | Google Scholar
1Pathology & Immunology, Baylor College of Medicine, Houston, United States of America
2Rice University, Houston, United States of America
Find articles by So, S. in: JCI | PubMed | Google Scholar
1Pathology & Immunology, Baylor College of Medicine, Houston, United States of America
2Rice University, Houston, United States of America
Find articles by
Treangen, T.
in:
JCI
|
PubMed
|
Google Scholar
|
1Pathology & Immunology, Baylor College of Medicine, Houston, United States of America
2Rice University, Houston, United States of America
Find articles by Savidge, T. in: JCI | PubMed | Google Scholar
Published November 14, 2023 - More info
Targeted metagenomic sequencing is an emerging strategy to survey disease- specific microbiome biomarkers for clinical diagnosis and prognosis. However, this approach often yields inconsistent or conflicting results due to inadequate study power and sequencing bias. We introduce Taxa4Meta, a bioinformatics pipeline explicitly designed to compensate for technical and demographic bias. We designed and validated Taxa4Meta for accurate taxonomic profiling of 16S rRNA amplicon data acquired from different sequencing strategies. Taxa4Meta offers significant potential in identifying clinical dysbiotic features that can reliably predict human disease, validated comprehensively via re-analysis of individual patient 16S datasets. We leveraged the power of Taxa4Meta's pan-microbiome profiling to generate 16S-based classifiers that exhibited excellent utility for stratification of diarrheal patients with Clostridioides difficile infection, irritable bowel syndrome or inflammatory bowel diseases, which represent common misdiagnoses and pose significant challenges for clinical management. We believe that Taxa4Meta represents a new "best practices" approach to individual microbiome surveys that can be used to define gut dysbiosis at a population-scale level.